Bibliography
- Goss PE , IngleJN, PaterJNet al.: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J. Clin. Oncol.26(12), 1948–5526(2008).
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717(2005).
- Saphner T , TormeyDC, GrayR: Annual hazard rates of recurrence for breast cancer after primary therapy.J. Clin. Oncol.14, 2738–2746(1996).
- Fisher B , DignamJ, BryantJet al.: Five versus more than 5 years of tamoxifen for lymph-node negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst.93, 684–90(2001).
- Goss PE , IngleJN, MartinoSet al.: A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med.349, 1793–802(2003).
- Goss PE , IngleJN, MartinoSet al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.J. Natl Cancer Inst.97, 1262–1271(2005).
- Hillner BE , IngleJN, ChlebowskiRTet al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.J. Clin. Oncol.21, 4042–4057(2003).
- Jakesz R , SamoniggH, GreilRet al.: Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J. Clin. Oncol.23, 10s (Suppl. 527) (2005).
- Jakesz R , GreilR, GnantMet al.: Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl Cancer Inst.99, 1845–1853(2007).
- Mamounas EP , JeongJH, WickerhamDLet al.: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. Clin. Oncol.26, 1965–1971(2008).
- Muss HB , TuD, IngleJNet al.: Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup trial MA.17. J. Clin. Oncol.26, 1956–1964(2008).
- Brufsky A , HarkerWG, BeckJTet al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol.25, 829–836(2007).